MedPath

A multi-centre, multinational, phase 3, open-label extension trial to assess the safety of long-term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa - N/A

Conditions
Parkinson's Disease
Registration Number
EUCTR2004-000148-26-FI
Lead Sponsor
Schwarz BioSciences Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
360
Inclusion Criteria

- Subject is informed and given ample time and opportunity to think about his/her
participation in this trial and has given his/her written informed consent
- Subject is willing and able to comply with all trial requirements
- Subject has completed 4 months of maintenance treatment in the double-blind trial
SP515
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Subject has an ongoing serious adverse event in trial SP515 that is assessed as
related to study medication

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath